雲頂新耀-B(01952.HK)與鎂信健康達成戰略合作 為中國患者開發創新型支付方案
格隆匯7月20日丨雲頂新耀-B(01952.HK)宣佈,公司與業內領先的創新醫療支付服務提供商及中國最大的藥房福利管理平台之一鎂信健康科技有限公司("鎂信健康")達成戰略合作關係。
通過此次合作,公司將發揮鎂信健康的藥房福利管理的專業優勢來管理患者的用藥計劃,幫助他們安全、方便地獲得所需的藥品。公司還將致力於開發創新支付解決方案,以提高公司治療方案的可及性和可負擔能力,包括(1)對藥物處方的系統審查和醫療費用控制系統,以實現全流程的疾病管理服務;(2)開展援助計劃改善患者用藥體驗;及(3)建立商業保險計劃,盡最大可能減少患者的經濟負擔。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.